Effect upon Insulin Secretion of Physiologic Doses of Glucagon Administered via the Portal Vein
- 1 May 1967
- journal article
- research article
- Published by American Diabetes Association in Diabetes
- Vol. 16 (5) , 283-288
- https://doi.org/10.2337/diab.16.5.283
Abstract
Rapid endoportal injections of glucagon in a dose (1 ug.) which does not elevate the arterial glucagon concentration beyond the physiologic range caused a prompt rise in both mean arterial glucose and pancreaticoduodenal insulin concentration to a peak six minutes later. Hyperglycemia of similar magnitude produced by intravenous glucose infusion failed to elicit as great a rise in insulin release. With smaller doses of glucagon a more variable response was observed; however, in some dogs doses of glucagon which were too small to cause a significant change in arterial glucagon concentration did cause a rise in both glucose and insulin levels. It is concluded that glucagon administered in physiologic doses via the portal venous system elicits a greater rise in insulin release than can be attributed to the concomitant hyperglycemia and, as suggested by others, does possess the qualifications of a potentiator of insulin secretion.This publication has 7 references indexed in Scilit:
- Inhibition of Insulin Release by Norepinephrine in ManScience, 1966
- The effect of epinephrine on immunoreactive insulin levels in man.Journal of Clinical Investigation, 1966
- Effect of glucagon on serum insulin, plasma glucose and free fatty acids in manMetabolism, 1966
- GLUCAGON ANTIBODIES AND AN IMMUNOASSAY FOR GLUCAGON*Journal of Clinical Investigation, 1961
- IMMUNOASSAY OF ENDOGENOUS PLASMA INSULIN IN MANJournal of Clinical Investigation, 1960
- Secretion of the Hyperglycemic-Glycogenolytic Factor in Normal DogsAmerican Journal of Physiology-Legacy Content, 1952
- Effects of the Hyperglycemic-Glycogenolytic Factor (HGF), Epinephrine and Insulin in Normal and Depancreatized Dogs.Experimental Biology and Medicine, 1952